Can a New Drug Candidate Cure Pancreatic Cancer?

Can a New Drug Candidate Cure Pancreatic Cancer? - UCSF

A new drug candidate permanently modifies a wily cancer-causing mutation, paving the way for making pancreatic cancer treatable, ...

Researchers have designed a candidate drug that could help make pancreatic cancer, which is almost always fatal, a treatable, perhaps even curable, condition.

Breakthrough for pancreatic cancer treatment - Drug Target Review

Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.

Investigational mRNA Vaccine Induced Persistent Immune ...

An experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate autogene ...

Chemo Boosts KRAS Inhibitor Against Pancreatic Cancer - NCI

A newer class of drugs that target pancreatic cancer may get a helping hand from an old treatment workhorse: chemotherapy. Two new studies ...

Study Shows Promise of New Anti-KRAS Drug for Pancreatic Cancer

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS successfully shrunk tumors or stopped ...

Opening a New Front Against Pancreatic Cancer

A new type of investigational therapeutic in development for pancreatic cancer has shown unprecedented tumor-fighting abilities in preclinical models of the ...

Drug Repurposing, an Attractive Strategy in Pancreatic Cancer ...

Repurposing of non-oncology drugs in PC treatment represents a very promising therapeutic option and different compounds are currently being considered as ...

Immunotherapy for Pancreatic Cancer

Immunotherapy for pancreatic cancer is currently in clinical trials, providing potential new options for patients with this difficult-to-treat cancer.

CAN-2409 Receives FDA Orphan Drug Designation in Pancreatic ...

CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

Drug Repurposing Opportunities in Pancreatic Ductal ...

In the past years, several studies have been investigating the potential of drug repurposing candidates for the treatment of pancreatic cancer, as single agents ...

Pancreatic Cancer Drug Candidate Targets Elusive, but Common, K ...

Pancreatic cancer treatments may be in reach now that a drug candidate has been shown to inhibit a KRAS mutation prevalent in the disease.

A newly designed drug candidate can make pancreatic cancer ...

Researchers at UC San Francisco have created a medication that might potentially provide a cure for pancreatic cancer, an almost always ...

Skip Viragh Center for Pancreatic Cancer - Johns Hopkins Medicine

Lee's approach could make curative surgery an option for many more patients. It combines anticancer drugs, a pancreatic cancer vaccine, an exciting new type of ...

Developing New Pancreatic Cancer Drugs: From Laboratory to ...

Let's look at a hypothetical drug and the journey it must take from a scientist's idea to becoming an approved treatment option for pancreatic cancer. A ...

Could a Georgetown Lab Finding Lead to New Treatment in ...

Now, for the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining ...

Candel Therapeutics Receives FDA Orphan Drug Designation for ...

... candidate, for the treatment of pancreatic cancer ... Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer.

FL118, Drug Candidate Discovered at Roswell Park, Granted FDA ...

... LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.

Verastem Oncology Receives FDA Orphan Drug Designation for ...

“The FDA Orphan Drug Designation for the combination of avutometinib and defactinib for the treatment of pancreatic cancer recognizes the ...

Four-Drug Combination Tested in Metastatic Pancreatic Cancer

This trial is for patients with metastatic pancreatic cancer whose first line of treatment has not stopped the disease (second-line therapy).